1. Home
  2. SBI vs GNLX Comparison

SBI vs GNLX Comparison

Compare SBI & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SBI
  • GNLX
  • Stock Information
  • Founded
  • SBI 1992
  • GNLX 2001
  • Country
  • SBI United States
  • GNLX United States
  • Employees
  • SBI N/A
  • GNLX N/A
  • Industry
  • SBI Finance/Investors Services
  • GNLX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SBI Finance
  • GNLX Health Care
  • Exchange
  • SBI Nasdaq
  • GNLX Nasdaq
  • Market Cap
  • SBI 106.2M
  • GNLX 94.0M
  • IPO Year
  • SBI N/A
  • GNLX 2023
  • Fundamental
  • Price
  • SBI $7.44
  • GNLX $2.42
  • Analyst Decision
  • SBI
  • GNLX Strong Buy
  • Analyst Count
  • SBI 0
  • GNLX 4
  • Target Price
  • SBI N/A
  • GNLX $17.75
  • AVG Volume (30 Days)
  • SBI 39.5K
  • GNLX 159.0K
  • Earning Date
  • SBI 01-01-0001
  • GNLX 05-06-2025
  • Dividend Yield
  • SBI 4.52%
  • GNLX N/A
  • EPS Growth
  • SBI N/A
  • GNLX N/A
  • EPS
  • SBI N/A
  • GNLX N/A
  • Revenue
  • SBI N/A
  • GNLX N/A
  • Revenue This Year
  • SBI N/A
  • GNLX N/A
  • Revenue Next Year
  • SBI N/A
  • GNLX N/A
  • P/E Ratio
  • SBI N/A
  • GNLX N/A
  • Revenue Growth
  • SBI N/A
  • GNLX N/A
  • 52 Week Low
  • SBI $6.96
  • GNLX $1.60
  • 52 Week High
  • SBI $8.00
  • GNLX $5.89
  • Technical
  • Relative Strength Index (RSI)
  • SBI 38.77
  • GNLX 43.88
  • Support Level
  • SBI $7.43
  • GNLX $2.42
  • Resistance Level
  • SBI $7.51
  • GNLX $2.78
  • Average True Range (ATR)
  • SBI 0.05
  • GNLX 0.24
  • MACD
  • SBI -0.01
  • GNLX 0.00
  • Stochastic Oscillator
  • SBI 5.56
  • GNLX 11.43

About SBI Western Asset Intermediate Muni Fund Inc

Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes. Under normal market conditions, the Fund will invest at least 80% of its total assets in municipal obligations. In addition, under normal market conditions, the Fund will invest at least 80% of its total assets in debt securities that are, at the time of investment, rated investment grade by a nationally recognized statistical rating organization or, if unrated, of equivalent quality as determined by the investment manager. The Fund also maintains a dollar-weighted average effective maturity of between three and ten years.

About GNLX Genelux Corporation

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.

Share on Social Networks: